Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

People taking Eli Lilly and Co.'s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the medications.

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Brigham Buhler, a MAHA influencer and biotech entrepreneur, has Robert F. Kennedy’s ear. But will RFK listen to his call to ...

Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...

Here's what Casey Means, President Trump's pick for surgeon general has said about childhood vaccines, pesticides, autism and ...

Merck Animal Health is investing $895 million in its Kansas facility. Novo Nordisk anticipates Wegovy sales recovery ...

We expected miracles; what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...

A doctor has issued an warning as to why Ozempic shouldn't be used for weight loss as it does one alarming thing to body.

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...